Pfizer Confirms License of Families of Spinal Muscular Atrophy Quinazoline Drug Program from Repligen

Pfizer Confirms License of Families of Spinal Muscular Atrophy Quinazoline Drug Program from Repligen

By: Latest Articles from Benzinga.com

Posted on January 03, 2013 at 09:34 AM EST

Repligen Corporation (NASDAQ: RGEN ) announced today that it has entered into an exclusive worldwide licensing agreement with Pfizer Inc. (NYSE: PFE ) to advance Repligen's spinal muscular atrophy (SMA) program, originally in-licensed from Families of SMA (FSMA). (c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights

Related Stocks:

NewStar Financial, Inc. Pfizer, Inc. Repligen Corp

Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates